<DOC>
	<DOCNO>NCT00002432</DOCNO>
	<brief_summary>To evaluate safety efficacy foscarnet induction therapy treatment AIDS patient experience first episode cytomegalovirus ( CMV ) retinitis . To evaluate safety efficacy foscarnet maintenance therapy treatment AIDS patient experience CMV retinitis .</brief_summary>
	<brief_title>A Study Foscarnet Treatment Cytomegalovirus ( CMV ) Eyes Patients With AIDS</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Prior Medication : Allowed : Ganciclovir ( DHPG ) . Exclusion Criteria Coexisting Condition : Patients follow excluded : Any clinically significant pulmonary neurologic impairment ( e.g. , patient intubate comatose ) . Corneal , lens , vitreous opacification precludes examination fundus , evidence tuberculotic , diabetic , and/or hypertensive retinopathy . Known allergy foscarnet . Concurrent Medication : Excluded : Nephrotoxic drug . Acyclovir . Patients follow excluded : Any clinically significant pulmonary neurologic impairment ( e.g. , patient intubate comatose ) . Corneal , lens , vitreous opacification precludes examination fundus , evidence tuberculotic , diabetic , and/or hypertensive retinopathy . Known allergy foscarnet . Prior Medication : Excluded within 7 day study entry : Immunomodulators . Biologic response modifier . Investigational agent ( ganciclovir ) . Patients AIDS define CDC , manifest first episode cytomegalovirus ( CMV ) retinitis identify characteristic ophthalmoscopic appearance verify fundus photography . Patients must able give informed consent . Patients enter study ganciclovir toxicity receive ganciclovir therapy result either absolute neutrophil count fall &lt; 750 cells/mm3 platelet count fall &lt; 50000 platelets/mm3 two separate occasion either : A ganciclovir induction regimen 7.5 mg ( ) /kg/day divide dos . A maintenance regimen 5 mg ( ) /kg/day single daily dose . Patients enter study ganciclovir treatment failure meet one follow criterion : CMV retinitis progression occur either 1 ) end 10 21 day induction course ganciclovir ( 7.5 10 mg/kg/day divide dos ) 2 ) first 28 day maintenance ganciclovir therapy ( 5 mg ( ) /kg/day , least 5 days/week ) maintenance therapy begin within 1 week complete induction therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 1990</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>